Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771240 | 0.90 | DRD2 (0.47) | DRD2SYKMTNR1AMTNR1BITGA4 | |
| SCHEMBL14974874 | 0.88 | DRD2 (0.46) | DRD2SYKMTNR1AMTNR1BITGA4 | |
| SCHEMBL4582959 | 0.84 | DRD2 (0.49) | DRD2SYKMTNR1AMTNR1BITGA4 | |
| SCHEMBL8242919 | 0.83 | DRD2 (0.48) | DRD2SYKMTNR1AMTNR1BITGA4 | |
| SCHEMBL6531538 | 0.82 | SYK (0.52) | SYKMALT1IDO1CTSSCTSK | |
| SCHEMBL27406074 | 0.82 | SYK (0.52) | SYKMALT1IDO1CTSSCTSK | |
| SCHEMBL27406072 | 0.82 | SYK (0.52) | SYKMALT1IDO1CTSSCTSK | |
| SCHEMBL8660697 | 0.78 | PPARA (0.44) | SYKCTSSCTSKEPHX2 | |
| SCHEMBL31389109 | 0.77 | CTSS (0.43) | SYKAAK1CTSSCTSK | |
| SCHEMBL31724161 | 0.77 | NPSR1 (0.43) | SYKMTNR1AMTNR1BCACNA1BCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | DRD2 4708/4885SYK 1211/4885MTNR1A 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.